Cellceutix has completed another study in the research of their new compound, KM-391, being developed to treat the core symptoms of autism.
Cellceutix said that its team has identified an animal model and has been successful in chemically inducing these characteristics in the model.
KM-391 has shown to be successful in altering the serotonin and brain plasticity levels resulting in physical and behavioural changes in the model that are similar to the 'non-autistic' control groups.
The company''s latest research on KM-391 involved physical measurements of serotonin levels in the cerebral cortex, hippocampus, and caudate nucleus areas of the brain.
In the study, several groups of rats were established with two of the groups being injected to induce the symptoms of autism.
After 48 days, the brains were assayed for serotonin by ELISA with the data showing that the administration of KM-391 increased serotonin levels in all 3 regions of the brain, from very low levels as observed with the induced autism to normal levels as observed in placebo treated control which received no treatment.
George Evans, CEO of Cellceutix, said: "This new data is highly relevant as it reinforces the data from previous studies and further solidifies our contention that serotonin levels in multiple brain regions may be a necessary key to the autism treatments."